Curated News
By: NewsRamp Editorial Staff
July 21, 2026
BioElectronics Expands HQ for ActiPatch and RecoveryRx Fulfillment
TLDR
- BioElectronics expands headquarters to support Electrome's ActiPatch launch, creating new service revenue and fulfillment advantages.
- BioElectronics leased adjacent space for a fulfillment center, providing inventory storage, order processing, and returns management per agreement with Electrome.
- The expansion enables efficient distribution of drug-free pain relief devices, improving access to non-invasive treatments for patients.
- ActiPatch will be sold directly to consumers in new packaging, offering an innovative drug-free option for pain management.
Impact - Why it Matters
This expansion is important because it enables BioElectronics to scale its fulfillment operations, directly supporting the commercial launch of drug-free pain relief devices like ActiPatch and RecoveryRx. For consumers, this means increased access to non-invasive, non-opioid pain management options, which could help address the opioid crisis and provide alternative treatments for chronic pain. The partnership with Electrome also suggests a growing market for bioelectronic therapies, offering patients more choices for pain relief without drugs.
Summary
BioElectronics Corporation (OTC: BIEL) has announced the expansion of its Maryland headquarters by leasing an adjacent office suite to serve as a dedicated storage and fulfillment center. This move supports new commercial activity involving its flagship products, ActiPatch and RecoveryRx. The expansion follows a Fulfillment Services and Distribution Control Agreement with Electrome Corporation, under which BioElectronics will provide inventory receiving, storage, order processing, packing, shipping coordination, and returns-management services.
Electrome is preparing for a direct-to-consumer launch of ActiPatch in newly designed branded packaging. BioElectronics expects the expanded facility to handle inventory and process individual consumer orders generated through Electrome's planned sales channel. The fulfillment center will also support anticipated orders for RecoveryRx, an FDA-cleared prescription device for postoperative and musculoskeletal pain. Kelly Whelan, President of BioElectronics, stated that the expansion strengthens commercial infrastructure and creates a service-based revenue opportunity. Erik A. Nilsen, PhD, CEO of Electrome, highlighted the importance of having an experienced fulfillment partner with direct product knowledge.
Under the agreement, BioElectronics will receive monthly storage fees, pick-and-pack fees, and additional charges for returns and special projects, with a monthly minimum for pick-and-pack services. Management believes this provides a scalable platform for Electrome's commercialization while maintaining oversight of inventory handling, quality controls, and shipping. The additional capacity may also support future fulfillment for other partners. BioElectronics develops bioelectronic therapies using pulsed shortwave therapy, with products including ActiPatch, RecoveryRx, and RecoveryRx Veterinary. Electrome commercializes similar technology through its PAINKILLER™ platform across multiple channels, with plans for big-box retail and AI-enabled therapy personalization.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BioElectronics Expands HQ for ActiPatch and RecoveryRx Fulfillment
